452 related articles for article (PubMed ID: 29950611)
1. S100B and LDH as early prognostic markers for response and overall survival in melanoma patients treated with anti-PD-1 or combined anti-PD-1 plus anti-CTLA-4 antibodies.
Wagner NB; Forschner A; Leiter U; Garbe C; Eigentler TK
Br J Cancer; 2018 Aug; 119(3):339-346. PubMed ID: 29950611
[TBL] [Abstract][Full Text] [Related]
2. Prognostic factors and outcomes in metastatic uveal melanoma treated with programmed cell death-1 or combined PD-1/cytotoxic T-lymphocyte antigen-4 inhibition.
Heppt MV; Heinzerling L; Kähler KC; Forschner A; Kirchberger MC; Loquai C; Meissner M; Meier F; Terheyden P; Schell B; Herbst R; Göppner D; Kiecker F; Rafei-Shamsabadi D; Haferkamp S; Huber MA; Utikal J; Ziemer M; Bumeder I; Pfeiffer C; Schäd SG; Schmid-Tannwald C; Tietze JK; Eigentler TK; Berking C
Eur J Cancer; 2017 Sep; 82():56-65. PubMed ID: 28648699
[TBL] [Abstract][Full Text] [Related]
3. Serum S100B and LDH at Baseline and During Therapy Predict the Outcome of Metastatic Melanoma Patients Treated with BRAF Inhibitors.
Gassenmaier M; Lenders MM; Forschner A; Leiter U; Weide B; Garbe C; Eigentler TK; Wagner NB
Target Oncol; 2021 Mar; 16(2):197-205. PubMed ID: 33555543
[TBL] [Abstract][Full Text] [Related]
4. Serum lactate dehydrogenase as an early marker for outcome in patients treated with anti-PD-1 therapy in metastatic melanoma.
Diem S; Kasenda B; Spain L; Martin-Liberal J; Marconcini R; Gore M; Larkin J
Br J Cancer; 2016 Feb; 114(3):256-61. PubMed ID: 26794281
[TBL] [Abstract][Full Text] [Related]
5. Relevance of serum biomarkers associated with melanoma during follow-up of anti-CTLA-4 immunotherapy.
Felix J; Cassinat B; Porcher R; Schlageter MH; Maubec E; Pages C; Baroudjian B; Homyrda L; Boukouaci W; Tamouza R; Bagot M; Caignard A; Toubert A; Lebbé C; Moins-Teisserenc H
Int Immunopharmacol; 2016 Nov; 40():466-473. PubMed ID: 27728898
[TBL] [Abstract][Full Text] [Related]
6. Lack of elevation of serum S100B in patients with metastatic melanoma as a predictor of outcome after induction with an autologous vaccine of proliferating tumor cells and dendritic cells.
Schiltz PM; Dillman RO; Korse CM; Cubellis JM; Lee GJ; De Gast GC
Cancer Biother Radiopharm; 2008 Apr; 23(2):214-21. PubMed ID: 18454690
[TBL] [Abstract][Full Text] [Related]
7. Diagnostic performance of early increase in S100B or LDH as outcome predictor for non-responsiveness to anti-PD-1 monotherapy in advanced melanoma.
Rozeman EA; Versluis JM; Moritz R; Wilgenhof S; van Thienen JV; Haanen JBAG; van de Heuvel MM; Blank CU; van Rossum HH
Clin Chim Acta; 2022 Aug; 533():71-78. PubMed ID: 35709988
[TBL] [Abstract][Full Text] [Related]
8. Outcome of melanoma patients with elevated LDH treated with first-line targeted therapy or PD-1-based immune checkpoint inhibition.
Knispel S; Gassenmaier M; Menzies AM; Loquai C; Johnson DB; Franklin C; Gutzmer R; Hassel JC; Weishaupt C; Eigentler T; Schilling B; Schummer P; Sirokay J; Kiecker F; Owen CN; Fleischer MI; Cann C; Kähler KC; Mohr P; Bluhm L; Niebel D; Thoms KM; Goldinger SM; Reinhardt L; Meier F; Berking C; Reinhard R; Susok L; Ascierto PA; Drexler K; Pföhler C; Tietze J; Heinzerling L; Livingstone E; Ugurel S; Long GV; Stang A; Schadendorf D; Zimmer L
Eur J Cancer; 2021 May; 148():61-75. PubMed ID: 33735811
[TBL] [Abstract][Full Text] [Related]
9. S100B and lactate dehydrogenase as response and progression markers during treatment with vemurafenib in patients with advanced melanoma.
Abusaif S; Jradi Z; Held L; Pflugfelder A; Weide B; Meier F; Garbe C; Eigentler TK
Melanoma Res; 2013 Oct; 23(5):396-401. PubMed ID: 23907232
[TBL] [Abstract][Full Text] [Related]
10. Investigation of clinical factors associated with longer overall survival in advanced melanoma patients treated with sequential ipilimumab.
Muto Y; Kitano S; Tsutsumida A; Namikawa K; Takahashi A; Nakamura Y; Yamanaka T; Yamamoto N; Yamazaki N
J Dermatol; 2019 Jun; 46(6):498-506. PubMed ID: 30945333
[TBL] [Abstract][Full Text] [Related]
11. Serum S100B levels correlate with stage, N status, mitotic rate and disease outcome in melanoma patients independent to LDH.
Karonidis A; Mantzourani M; Gogas H; Tsoutsos D
J BUON; 2017; 22(5):1296-1302. PubMed ID: 29135116
[TBL] [Abstract][Full Text] [Related]
12. Primary tumour category, site of metastasis, and baseline serum S100B and LDH are independent prognostic factors for survival in metastatic melanoma patients treated with anti-PD-1.
Janka EA; Ványai B; Szabó IL; Toka-Farkas T; Várvölgyi T; Kapitány A; Szegedi A; Emri G
Front Oncol; 2023; 13():1237643. PubMed ID: 37664072
[TBL] [Abstract][Full Text] [Related]
13. Serum S100B is suitable for prediction and monitoring of response to chemoimmunotherapy in metastatic malignant melanoma.
Hamberg AP; Korse CM; Bonfrer JM; de Gast GC
Melanoma Res; 2003 Feb; 13(1):45-9. PubMed ID: 12569284
[TBL] [Abstract][Full Text] [Related]
14. Distinct Immune Cell Populations Define Response to Anti-PD-1 Monotherapy and Anti-PD-1/Anti-CTLA-4 Combined Therapy.
Gide TN; Quek C; Menzies AM; Tasker AT; Shang P; Holst J; Madore J; Lim SY; Velickovic R; Wongchenko M; Yan Y; Lo S; Carlino MS; Guminski A; Saw RPM; Pang A; McGuire HM; Palendira U; Thompson JF; Rizos H; Silva IPD; Batten M; Scolyer RA; Long GV; Wilmott JS
Cancer Cell; 2019 Feb; 35(2):238-255.e6. PubMed ID: 30753825
[TBL] [Abstract][Full Text] [Related]
15. Serum S100B, lactate dehydrogenase and brain metastasis are prognostic factors in patients with distant melanoma metastasis and systemic therapy.
Weide B; Richter S; Büttner P; Leiter U; Forschner A; Bauer J; Held L; Eigentler TK; Meier F; Garbe C
PLoS One; 2013; 8(11):e81624. PubMed ID: 24312329
[TBL] [Abstract][Full Text] [Related]
16. Timing and type of immune checkpoint therapy affect the early radiographic response of melanoma brain metastases to stereotactic radiosurgery.
Qian JM; Yu JB; Kluger HM; Chiang VL
Cancer; 2016 Oct; 122(19):3051-8. PubMed ID: 27285122
[TBL] [Abstract][Full Text] [Related]
17. Metastatic uveal melanoma showing durable response to anti-CTLA-4 and anti-PD-1 combination therapy after experiencing progression on anti-PD-1 therapy alone.
Afzal MZ; Mabaera R; Shirai K
J Immunother Cancer; 2018 Feb; 6(1):13. PubMed ID: 29433557
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of clinicopathological factors in PD-1 response: derivation and validation of a prediction scale for response to PD-1 monotherapy.
Nosrati A; Tsai KK; Goldinger SM; Tumeh P; Grimes B; Loo K; Algazi AP; Nguyen-Kim TDL; Levesque M; Dummer R; Hamid O; Daud A
Br J Cancer; 2017 Apr; 116(9):1141-1147. PubMed ID: 28324889
[TBL] [Abstract][Full Text] [Related]
19. Developing a score system to predict therapeutic outcomes to anti-PD-1 immunotherapy in metastatic melanoma.
Indini A; Di Guardo L; Cimminiello C; Prisciandaro M; Randon G; De Braud F; Del Vecchio M
Tumori; 2019 Dec; 105(6):465-473. PubMed ID: 31446882
[TBL] [Abstract][Full Text] [Related]
20. Impact of clinicopathological characteristics on survival in patients treated with immune checkpoint inhibitors for metastatic melanoma.
Zhao B; Zhao H; Zhao J
Int J Cancer; 2019 Jan; 144(1):169-177. PubMed ID: 30121946
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]